Home > Insider Trading > Filing (0001209191-21-030141)

Filing Details

Accession Number:: 0001209191-21-030141
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-05-04 13:00:00
Reporting Period:: 2021-05-03

Accepted Time:: 2021-05-04 20:31:21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1783183	Phathom Pharmaceuticals Inc.	PHAT	Pharmaceutical Preparations (2834)	824151574

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1791412	Azmi Nabulsi	C/O Phathom Pharmaceuticals, Inc. 100 Campus Drive, Suite 102 Florham Pak NJ 07932	Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-05-03	4,290	$37.85	775,910	No	4	S	Indirect	By Trust
Common Stock	Disposition	2021-05-03	5,753	$38.59	770,157	No	4	S	Indirect	By Trust
Common Stock	Disposition	2021-05-04	1,968	$36.15	768,189	No	4	S	Indirect	By Trust
Common Stock	Disposition	2021-05-04	1,400	$37.09	766,789	No	4	S	Indirect	By Trust
Common Stock	Disposition	2021-05-04	1,089	$37.86	765,700	No	4	S	Indirect	By Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Trust
No	4	S	Indirect	By Trust
No	4	S	Indirect	By Trust
No	4	S	Indirect	By Trust
No	4	S	Indirect	By Trust

Footnotes

All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.15 to $38.12. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.18 to $38.97. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.66 to $36.64. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.66 to $37.60. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.7550 to $38.06. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.